Skip to content
Screener

Vor Biopharma VOR Return on equity

Return on equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
25.7%-4.5pp
Amgen logo
AmgenAMGN
91.5%-7.7pp
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
23.5%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-28.6%+3.2pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-44%+26.2pp
Vera Therapeutics logo
Vera TherapeuticsVERA
-71.3%+296pp

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$1.28B+392%
Enterprise value$1.12B+902%

Returns & leverage

See full
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Calculated from Vor Biopharma’s reported figures.

Based on trailing twelve months.

The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 8:31 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-220689

FAQ

What is Vor Biopharma's return on equity?
Vor Biopharma (VOR) reported return on equity of -125.4% in Q1 2025.
How has Vor Biopharma's return on equity changed year-over-year?
Vor Biopharma's return on equity decreased by 84.3% year-over-year, from -68.1% to -125.4%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Vor Biopharma's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude